Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)

Next Previous
Trial Profile

A Multi-center, Randomized, Double-blind, Placebo, and Active-controlled Phase 2b Dose-finding Study of QGE031 as add-on Therapy to Investigate the Efficacy and Safety in Patients With Chronic Spontaneous Urticaria (CSU)

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ligelizumab (Primary) ; Omalizumab
  • Indications Chronic urticaria
  • Focus Therapeutic Use
  • Sponsors Novartis; Novartis Pharmaceuticals

    • Most Recent Events

    • 14 Nov 2022 Results of an analysis overall HRQoL, association of SIS7 and DLQI scores with disease activity and QoL in patients with and without hives and itch presented at the 2022 Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology
    • 28 Feb 2022 Results of post-hoc analysis assessing response to ligelizumab in CSU patients who were either BHRA negative or BHRA positive at baseline, presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
    • 28 Feb 2022 Results assessing ffect of ligelizumab, omalizumab and placebo treatment on weekly-angioedema-activity-score (AAS7) and derma-tology-life-quality-index (DLQI) of CSU patients with and without angioedema, presented at the 2022 Annual Meeting of the American Academy of Allergy, Asthma and Immunology.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top